Trials / Completed
CompletedNCT05966272
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 injection | single dose |
| DRUG | HRS9531 injection Placebo | single dose |
Timeline
- Start date
- 2023-08-12
- Primary completion
- 2024-09-24
- Completion
- 2024-09-24
- First posted
- 2023-07-28
- Last updated
- 2025-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05966272. Inclusion in this directory is not an endorsement.